National Institute for Health and Care Excellence

Board meeting

22 July 2022

Title

Early value assessment for medtech

Purpose of paper

For discussion and information

Board action required

The Board is asked to comment on the approach being taken in Early Value Assessment for medical technologies.

Brief summary

These slides are intended to provide the Board with an update on the progress of the business plan priority objective 3, Early Value Assessment. They describe the high-level process and key activities to date, as well as detailing the next steps.

Board sponsor

Mark Chapman, Interim Director of Medical Technology and Digital Evaluation